Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

mRNA levels of BACE1 and its interacting proteins, RTN3 and PPIL2, correlate in human post mortem brain tissue.

Beyer N, Coulson DT, Quinn JG, Brockbank S, Hellemans J, Irvine GB, Ravid R, Johnston JA.

Neuroscience. 2014 Aug 22;274:44-52. doi: 10.1016/j.neuroscience.2014.05.020. Epub 2014 May 20.

PMID:
24853053
2.

α-Synuclein mRNA and soluble α-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease.

Quinn JG, Coulson DT, Brockbank S, Beyer N, Ravid R, Hellemans J, Irvine GB, Johnston JA.

Brain Res. 2012 Jun 12;1459:71-80. doi: 10.1016/j.brainres.2012.04.018. Epub 2012 Apr 17.

PMID:
22560502
3.

Zinc transporter mRNA levels in Alzheimer's disease postmortem brain.

Beyer N, Coulson DT, Heggarty S, Ravid R, Hellemans J, Irvine GB, Johnston JA.

J Alzheimers Dis. 2012;29(4):863-73. doi: 10.3233/JAD-2012-112105.

PMID:
22349685
4.

BACE1 mRNA expression in Alzheimer's disease postmortem brain tissue.

Coulson DT, Beyer N, Quinn JG, Brockbank S, Hellemans J, Irvine GB, Ravid R, Johnston JA.

J Alzheimers Dis. 2010;22(4):1111-22. doi: 10.3233/JAD-2010-101254.

PMID:
20930286
5.

ZnT3 mRNA levels are reduced in Alzheimer's disease post-mortem brain.

Beyer N, Coulson DT, Heggarty S, Ravid R, Irvine GB, Hellemans J, Johnston JA.

Mol Neurodegener. 2009 Dec 23;4:53. doi: 10.1186/1750-1326-4-53.

6.

Variation in RTN3 and PPIL2 genes does not influence platelet membrane beta-secretase activity or susceptibility to alzheimer's disease in the northern Irish population.

Carson R, McKnight AJ, Todd S, Liu WW, Heggarty S, Craig D, McGuinness B, Irvine GB, Passmore AP, Johnston JA.

Neuromolecular Med. 2009;11(4):337-44. doi: 10.1007/s12017-009-8080-3.

PMID:
19669607
7.

A novel reciprocal and biphasic relationship between membrane cholesterol and beta-secretase activity in SH-SY5Y cells and in human platelets.

Liu WW, Todd S, Coulson DT, Irvine GB, Passmore AP, McGuinness B, McConville M, Craig D, Johnston JA.

J Neurochem. 2009 Jan;108(2):341-9. doi: 10.1111/j.1471-4159.2008.05753.x.

8.

IQ motif selectivity in human IQGAP1: binding of myosin essential light chain and S100B.

Pathmanathan S, Elliott SF, McSwiggen S, Greer B, Harriott P, Irvine GB, Timson DJ.

Mol Cell Biochem. 2008 Nov;318(1-2):43-51. doi: 10.1007/s11010-008-9855-9. Epub 2008 Jun 28.

PMID:
18587628
9.

BACE1 polymorphisms do not influence platelet membrane beta-secretase activity or genetic susceptibility for Alzheimer's disease in the Northern Irish population.

Todd S, McKnight AJ, Liu WW, Carson R, Heggarty S, McGuinness B, Irvine GB, Craig D, Passmore AP, Johnston JA.

Neuromolecular Med. 2008;10(4):368-76. doi: 10.1007/s12017-008-8045-y. Epub 2008 Jun 26.

PMID:
18581272
10.

Identification of valid reference genes for the normalization of RT qPCR gene expression data in human brain tissue.

Coulson DT, Brockbank S, Quinn JG, Murphy S, Ravid R, Irvine GB, Johnston JA.

BMC Mol Biol. 2008 May 6;9:46. doi: 10.1186/1471-2199-9-46.

11.

Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases.

Irvine GB, El-Agnaf OM, Shankar GM, Walsh DM.

Mol Med. 2008 Jul-Aug;14(7-8):451-64. doi: 10.2119/2007-00100.Irvine. Review.

12.

Determination of molecular size by size-exclusion chromatography (gel filtration).

Irvine GB.

Curr Protoc Cell Biol. 2001 May;Chapter 5:Unit 5.5. doi: 10.1002/0471143030.cb0505s06.

PMID:
18228373
13.

Elevated platelet beta-secretase activity in mild cognitive impairment.

Liu WW, Todd S, Craig D, Passmore AP, Coulson DT, Murphy S, Irvine GB, Johnston JA.

Dement Geriatr Cogn Disord. 2007;24(6):464-8. Epub 2007 Nov 7.

PMID:
17986817
14.

Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease.

Ross OA, Gosal D, Stone JT, Lincoln SJ, Heckman MG, Irvine GB, Johnston JA, Gibson JM, Farrer MJ, Lynch T.

Mech Ageing Dev. 2007 May-Jun;128(5-6):378-82. Epub 2007 Apr 24.

15.

Platelet beta-secretase activity is increased in Alzheimer's disease.

Johnston JA, Liu WW, Coulson DT, Todd S, Murphy S, Brennan S, Foy CJ, Craig D, Irvine GB, Passmore AP.

Neurobiol Aging. 2008 May;29(5):661-8. Epub 2006 Dec 14.

PMID:
17174011
16.

Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.

Amer DA, Irvine GB, El-Agnaf OM.

Exp Brain Res. 2006 Aug;173(2):223-33. Epub 2006 May 30. Review.

PMID:
16733698
17.

Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy.

Paleologou KE, Irvine GB, El-Agnaf OM.

Biochem Soc Trans. 2005 Nov;33(Pt 5):1106-10. Review.

PMID:
16246056
18.

Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's disease.

Johnston JA, Liu WW, Todd SA, Coulson DT, Murphy S, Irvine GB, Passmore AP.

Biochem Soc Trans. 2005 Nov;33(Pt 5):1096-100. Review.

PMID:
16246054
19.

Femoral neck fractures following Birmingham hip resurfacing.

Irvine GB.

J Bone Joint Surg Br. 2005 Oct;87(10):1445; author reply 1445. No abstract available.

PMID:
16189326
20.

Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD.

Gosal D, Ross OA, Wiley J, Irvine GB, Johnston JA, Toft M, Mata IF, Kachergus J, Hulihan M, Taylor JP, Lincoln SJ, Farrer MJ, Lynch T, Mark Gibson J.

Parkinsonism Relat Disord. 2005 Sep;11(6):349-52.

PMID:
16102999
21.

Alpha-synuclein aggregation.

Bodles AM, Irvine GB.

Protein Pept Lett. 2004 Jun;11(3):271-9. Review.

PMID:
15182228
22.

Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue.

Bodles AM, El-Agnaf OM, Greer B, Guthrie DJ, Irvine GB.

Neurosci Lett. 2004 Apr 8;359(1-2):89-93.

PMID:
15050719
23.

High-performance size-exclusion chromatography of peptides.

Irvine GB.

J Biochem Biophys Methods. 2003 Jun 30;56(1-3):233-42. Review.

PMID:
12834979
24.

Amino acid analysis. Precolumn derivatization methods.

Irvine GB, Davidson I.

Methods Mol Biol. 2003;211:123-31. No abstract available.

PMID:
12489426
25.

Aggregation and neurotoxicity of alpha-synuclein and related peptides.

el-Agnaf OM, Irvine GB.

Biochem Soc Trans. 2002 Aug;30(4):559-65. Review.

PMID:
12196137
26.
27.

Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins.

El-Agnaf OM, Irvine GB.

J Struct Biol. 2000 Jun;130(2-3):300-9. Review.

PMID:
10940234
28.

Studies on the aggregation and secondary structure of peptides derived from non-A beta component of Alzheimer's disease amyloid.

Irvine GB, El-Agnaf OM, Bodles AM, Guthrie DJ, Harriott P.

Biochem Soc Trans. 1998 Feb;26(1):S36. No abstract available.

PMID:
10909794
29.
30.
31.

Comparative studies on peptides representing the so-called tachykinin-like region of the Alzheimer Abeta peptide [Abeta(25-35)].

El-Agnaf OM, Irvine GB, Fitzpatrick G, Glass WK, Guthrie DJ.

Biochem J. 1998 Dec 1;336 ( Pt 2):419-27.

32.
33.

Amino acid analysis. Precolumn derivatization methods.

Irvine GB.

Methods Mol Biol. 1997;64:131-8. No abstract available.

PMID:
9116816
34.
35.

Conformations of beta-amyloid in solution.

el-Agnaf OM, Irvine GB, Guthrie DJ.

J Neurochem. 1997 Jan;68(1):437-9. No abstract available.

36.

Properties of some peptides related to amyloid beta-peptide.

el-Agnaf OM, Irvine GB, Guthrie DJ, Walsh DM.

Biochem Soc Trans. 1996 Feb;24(1):59S. No abstract available.

PMID:
8674733
37.

Studies on peptides containing the 25-35 sequence of amyloid beta peptide.

el-Agnaf OA, Guthrie DJ, Irvine GB.

Biochem Soc Trans. 1995 Feb;23(1):49S. No abstract available.

PMID:
7758762
38.

Successful syntheses of beta amyloid-(25-35)-peptide: a difficult sequence by N-(9-fluorenylmethoxycarbonyl) chemistry.

Guthrie DJ, el-Agnaf O, Harriott P, Irvine GB, Walker B.

Biochem Soc Trans. 1994 Nov;22(4):1052-4. Review. No abstract available.

PMID:
7698406
39.

A molecular dynamics study of Helix aspersa NPF.

Leung PS, Guthrie DJ, Irvine GB, Shaw C.

Biochem Soc Trans. 1994 Feb;22(1):8S. No abstract available.

PMID:
8206311
40.

N-(4-azido benzoyl)FnLRFamide, a putative photoaffinity label for the FMRFamide receptor.

Geraghty RF, Irvine GB, Williams CH.

Biochem Soc Trans. 1994 Feb;22(1):4S. No abstract available.

PMID:
8206263
42.
43.
44.

Biological activity and receptor binding properties of some analogues of pQDPFLRFamide.

Geraghty RF, Williams CH, Irvine GB, Evans PD, Cottrell GA.

Peptides. 1994;15(5):835-41.

PMID:
7984503
45.

Molecular-weight estimation for native proteins using size-exclusion high-performance liquid chromatography.

Irvine GB.

Methods Mol Biol. 1994;32:267-74. Review. No abstract available.

PMID:
7951727
46.

Amino acid analysis.

Irvine GB.

Methods Mol Biol. 1994;32:257-65. Review. No abstract available.

PMID:
7951726
47.

Biological activity and receptor binding properties of some C-terminally modified analogues of FMRFamide.

Geraghty RF, Irvine GB, Williams CH, Cottrell GA.

Peptides. 1994 Jan;15(1):73-81.

PMID:
7912430
48.

Conformational studies on heptapeptide analogues of the invertebrate neuropeptide FMRFamide.

Geraghty R, Guthrie DJ, Irvine GB, Williams CH.

Biochem Soc Trans. 1993 Aug;21 ( Pt 3)(3):261S. No abstract available.

PMID:
8224413
49.

Stabilisation of a bent conformation in a neurokinin A analogue by an a,a-dialkyl amino acid.

Hussain R, Guthrie DJ, Irvine GB, Stevenson PJ, Allen JM.

Biochem Soc Trans. 1993 Aug;21 ( Pt 3)(3):269S. No abstract available.

PMID:
8135925
50.

Serum neurone-specific enolase levels in patients with neuroendocrine and carcinoid tumours.

Cunningham RT, Johnston CF, Irvine GB, Buchanan KD.

Clin Chim Acta. 1992 Nov 30;212(3):123-31.

PMID:
1477975

Supplemental Content

Loading ...
Support Center